Anti-Hypertensive Drugs Market Is Likely to Experience a Tremendous Growth by 2029

Anti-Hypertensive Drugs Market is anticipated to grow at a significant CAGR during the forecast period. The major factors that are expected to fuel the market during the forecast period include a surge in the incidence of hypertension across the globe. The rise in awareness related to complications associated with hypertension is also a major factor that boosts the growth of the market. Moreover, an increase in the geriatric population and sedentary lifestyle are some key causes of hypertension, which in turn, is accelerating the demand for antihypertensive drugs. However, patent expirations are anticipated to hinder the growth of the market. Furthermore, the rise in research related to antihypertensive drugs is expected to offer a lucrative opportunity during the forecast period. Moreover, an increase in the incidence rate of CVD, owing to the rise in prevalence of stroke, diabetes, and hypertension patients is expected to drive the market.

Hypertension is defined as a long-term medical condition that is marked by the high pressure of blood in the arteries, which is persistently elevated. Antihypertensive drugs are used for the treatment of patients suffering from high blood pressure also known as hypertension. Hypertension is a major disorder accompanied by serious complications such as heart attack, heart failure, and dementia. Therefore, hypertension requires early diagnosis and treatment. Some of the drug class used for the treatment of hypertension include diuretics, ACE inhibitors, and vasodilators.

To Request a Sample of our Report on Anti-Hypertensive Drugs Market: https://www.omrglobal.com/request-sample/anti-hypertensive-drug-market

Market Coverage

· The market number available for - 2022-2030

· Base year- 2022

· Forecast period- 2021-2030

· Segment Covered

· Regions Covered- Globally

Competitive Landscape: Johnson & Johnson Services, Inc., Merck KGaA, and Daiichi Sankyo Co., Ltd., among others.

A full Report of Anti-Hypertensive Drugs Market is Available @ https://www.omrglobal.com/industry-reports/anti-hypertensive-drug-market

Antihypertensive Drugs Market Report by Segment

By Therapeutic Class

• Diuretics

• ACE Inhibitors

• Calcium Channel Blockers

• Vasodilators

• Beta-Adrenergic Blockers

• Others

By Distribution Channel

• Retail Pharmacy

• Hospital Pharmacy

• Online Pharmacy

Antihypertensive Drugs Market by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

https://www.somosxbox.com.mx/noticias-urgente/se-proyecta-que-el-valor-de-mercado-de-las-maquinas-de-moler-cafe-se-expanda-para-2029/120415/
https://ekz-crosstour.ch/news/marktausblick-fuer-musikinstrumente-2029-praesentiert-markteinblicke-und-eingehende-analysen/129110/
https://perualdia.net/valor-de-mercado-de-terminal-de-comunicacion-laser-proyectado-para-expandirse-en-2029/

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.